ClinicalTrials.gg
CompletedNCT00694369Updated Feb 9, 2022Results posted

A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)

A Phase 3 interventional study of Comparator: etoricoxib and Comparator: ibuprofen in Postoperative Dental Pain, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
588
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing etoricoxib in Pain — none open to participants now, 1 under way, none of them phase 3. Etoricoxib · Pain.

Enrollment
Largest of 14
588 · median 75
Started
2008
with 1 other
Phase 3
Only one
of the 14
Registered
2nd of 14
by date
Lead sponsor
3 of 14
Organon and Co

Among the 14 studies testing etoricoxib in Pain, this one has the largest enrollment, is one of 2 that started in 2008, is the only one in phase 3, and was the 2nd registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 14 studies testing etoricoxib in Pain is open now. The open studies under Pain, anywhere →

About etoricoxib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing etoricoxib in Pain as a file.
02

Study summary

The purpose of this study is to compare the pain relieving effect of different doses of MK0663 with placebo and other pain relievers/analgesics in patients with postoperative dental pain. Pain intensity and relief will be measured by the total pain relief score (TOPAR) and patient evaluation.

03

Conditions studied

  • Postoperative Dental Pain

Browse trials for

Keywords

  • Postoperative Dental Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be scheduled to have 2 or more third molars removed, at least 1 of which is partially embedded in bone and is impacted in the lower jaw
  • Patients must be experiencing moderate to severe pain following the dental procedure

Exclusion criteria

Exclusion Criteria:

  • Previous molar extraction within the past 45 days
  • Personal or family history of an inherited bleeding disorder
  • Uncontrolled high blood pressure
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
588 participants (actual)

Study arms

  • Experimental
    1

    etoricoxib 90 mg

    Drug: Comparator: etoricoxib

  • Experimental
    2

    etoricoxib 120 mg

    Drug: Comparator: etoricoxib

  • Active comparator
    3

    ibuprofen 2400 mg

    Drug: Comparator: ibuprofen

  • Active comparator
    4

    acetaminophen 2400 mg/codeine 240 mg

    Drug: Comparator: acetaminophen + codeine

  • Placebo comparator
    5

    Matching Placebo

    Drug: Comparator: placebo

Interventions

  • etoricoxib 90 mg; 120 mg (once daily) over three days.

  • ibuprofen 2400 mg (600 mg Q6h) over three Days

  • DrugComparator: acetaminophen + codeine

    Drug pages: Acetaminophen · Codeine

    acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days

  • DrugComparator: placebo

    matching placebo over three Days

06

What researchers measure

Primary outcomes

  1. Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)

    TOPAR6 was calculated by multiplying the pain relief (PR) score (0- to 4-point Likert scale, with 0=None, and 4=Complete for pain relief) at each time point by the duration (in hours) since the preceding time point, and summing these weighted values up to 6 hours post the initial Day 1 dose. The range of TOPAR6 score is 0 to 24.

    Time frame: Over the first 6 hours post the initial Day 1 dose of the study medication

Secondary outcomes

  1. Patient's Global Assessment of Study Medication at 24 Hours Post the Initial Day 1 Dose of the Study Medication

    Patient's Global Assessment of Study Medication was on 0- to 4- point scale, with 0=Poor, and 4=Excellent for patient's rating of the study medication for pain.

    Time frame: At 24 hours post the initial Day 1 dose of the study medication

07

Results

Posted Jan 29, 2010

Participant flow

Study Conducted at 3 investigational sites in the US. Patients were recruited from the sites patient pool and through advertising. A total of 588 patients were randomized. First Patient Entered 27-June-2008; First Patient In (randomized) on 03-July- 2008; Last Patient Last Visit 08-Jan-09

Participant flow — Overall Study
MilestonePlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 2400 mgAcetaminophen 2400 mg/Codeine 240 mg
Started461919719262
Completed451889518956
Not completed13236
Withdrew: Adverse event01013
Withdrew: Lost to follow-up00110
Withdrew: Physician decision00001
Withdrew: Protocol violation01000
Withdrew: Withdrawal by subject11112

Outcome measures

PrimaryTotal Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)

TOPAR6 was calculated by multiplying the pain relief (PR) score (0- to 4-point Likert scale, with 0=None, and 4=Complete for pain relief) at each time point by the duration (in hours) since the preceding time point, and summing these weighted values up to 6 hours post the initial Day 1 dose. The range of TOPAR6 score is 0 to 24.

Time frame:
Over the first 6 hours post the initial Day 1 dose of the study medication
Reported as:
Least squares mean · Units on a Scale
Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)
Units on a ScalePlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 2400 mgAcetaminophen 2400 mg/Codeine 240 mg
Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)5.08 ± 0.8616.10 ± 0.4215.73 ± 0.5915.67 ± 0.4211.83 ± 0.74
Statistical analysis
  • Placebo vs Etoricoxib 120 mg · ANOVA · p = <0.001 (0.05 critical level was used.)Step-down manner was used (p-value for 90-mg dose comparison was reported only if the p-value for 120-mg dose comparison is significant).
  • Placebo vs Etoricoxib 90 mg · ANOVA · p = <0.001 (0.05 critical level was used.)Step-down manner was used (p-value for 90-mg dose comparison was reported only if the p-value for 120-mg dose comparison is significant)
  • Etoricoxib 120 mg vs Ibuprofen 2400 mg · Difference in ls means: 0.06 · 95% CI -1.37 to 1.48Difference in Least squares means (LS Means) (etoricoxib minus ibuprofen)
  • Etoricoxib 90 mg vs Ibuprofen 2400 mg · Difference in ls means: 0.43 · 95% CI -0.73 to 1.60Difference in LS Means (etoricoxib minus ibuprofen)
  • Etoricoxib 120 mg vs Acetaminophen 2400 mg/Codeine 240 mg · Difference in ls means: 3.90 · 95% CI 2.04 to 5.76Difference in LS Means (etoricoxib minus acetaminophen/codeine)
  • Etoricoxib 90 mg vs Acetaminophen 2400 mg/Codeine 240 mg · Difference in ls means: 4.27 · 95% CI 2.61 to 5.94Difference in LS Means (etoricoxib minus acetaminophen/codeine)
  • Etoricoxib 90 mg vs Etoricoxib 120 mg · Difference in ls means: -0.38 · 95% CI -1.80 to 1.05Difference in LS Means (etoricoxib 120 mg minus etoricoxib 90 mg)
  • Placebo vs Ibuprofen 2400 mg · Difference in ls means: 10.59 · 95% CI 8.72 to 12.47Difference in LS Means (ibuprofen 2400 mg minus placebo)
  • Placebo vs Acetaminophen 2400 mg/Codeine 240 mg · Difference in ls means: 6.75 · 95% CI 4.53 to 8.97Difference in LS Means (acetaminophen 2400 mg/codeine 240 mg minus placebo)
SecondaryPatient's Global Assessment of Study Medication at 24 Hours Post the Initial Day 1 Dose of the Study Medication

Patient's Global Assessment of Study Medication was on 0- to 4- point scale, with 0=Poor, and 4=Excellent for patient's rating of the study medication for pain.

Time frame:
At 24 hours post the initial Day 1 dose of the study medication
Reported as:
Number · Participants
Patient's Global Assessment of Study Medication at 24 Hours Post the Initial Day 1 Dose of the Study Medication
ParticipantsPlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 2400 mgAcetaminophen 2400 mg/Codeine 240 mg
Poor1912761
Fair121252413
Good543204215
Very Good566267318
Excellent35128357
Statistical analysis
  • Placebo vs Etoricoxib 120 mg · stratified Wilcoxon rank sum test · p = <0.001 (0.05 critical level was used.)Step-down manner was used (p-value for 90-mg dose comparison was reported only if the p-value for 120-mg dose comparison is significant).
  • Placebo vs Etoricoxib 90 mg · stratified Wilcoxon rank sum test · p = <0.001 (0.05 critical level was used.)Step-down manner was used (p-value for 90-mg dose comparison was reported only if the p-value for 120-mg dose comparison is significant)
  • Etoricoxib 120 mg vs Ibuprofen 2400 mg · stratified Wilcoxon rank sum test · p = 0.161 (0.05 critical level was used.)Nominal p-value was provided in lieu of the 95% CI. Step-down manner was used, and the nominal p-value for 90-mg dose comparison was not reported.
  • Etoricoxib 120 mg vs Acetaminophen 2400 mg/Codeine 240 mg · stratified Wilcoxon rank sum test · p = 0.014 (0.05 critical level was used.)Nominal p-value was provided in lieu of the 95% CI. Step-down manner was used.
  • Etoricoxib 90 mg vs Acetaminophen 2400 mg/Codeine 240 mg · stratified Wilcoxon rank sum test · p = 0.007 (0.05 critical level was used.)Nominal p-value was provided in lieu of the 95% CI. Step-down manner was used.

Adverse events

Collected over Adverse experiences were collected from the Pre-surgery/Pre-treatment period through the 14 day safety follow-up period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/46 (0%)12/46 (26.1%)
Etoricoxib 90 mg—0/191 (0%)54/191 (28.3%)
Etoricoxib 120 mg—0/97 (0%)28/97 (28.9%)
Ibuprofen 2400 mg—0/192 (0%)57/192 (29.7%)
Acetaminophen 2400 mg/Codeine 240 mg—0/62 (0%)35/62 (56.5%)
Most frequent other events
Showing 10 of 90
Most frequent other events
EventPlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 2400 mgAcetaminophen 2400 mg/Codeine 240 mg
NauseaGastrointestinal disorders3/466/1914/9710/19223/62
VomitingGastrointestinal disorders1/462/1911/972/19215/62
DizzinessNervous system disorders2/464/1910/973/19210/62
HeadacheNervous system disorders6/4611/1915/978/1929/62
SomnolenceNervous system disorders0/464/1912/976/1925/62
FlushingVascular disorders2/460/1911/971/1920/62
Alveolar osteitisInfections and infestations0/468/1913/978/1921/62
HyperhidrosisSkin and subcutaneous tissue disorders1/461/1911/971/1922/62
DysgeusiaNervous system disorders0/462/1913/970/1920/62
BlepharospasmEye disorders1/460/1910/970/1920/62

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 2400 mgAcetaminophen 2400 mg/Codeine 240 mgTotal
Mean21.0 ± 3.021.8 ± 3.621.8 ± 3.521.6 ± 3.820.5 ± 2.821.5 ± 3.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 2400 mgAcetaminophen 2400 mg/Codeine 240 mgTotal
Female251135011537340
Male2178477725248
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 2400 mgAcetaminophen 2400 mg/Codeine 240 mgTotal
Hispanic or Latino1152255017155
Not Hispanic or Latino351397214244432
Unknown or Not Reported000011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 2400 mgAcetaminophen 2400 mg/Codeine 240 mgTotal
American Indian or Alaska Native012115
Asian0649019
Native Hawaiian or Other Pacific Islander011114
Black or African American2417317
White431748617356532
More than one race1531111
Unknown or Not Reported000000
Baseline Pain Intensity
Baseline Pain Intensity(Participants)PlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 2400 mgAcetaminophen 2400 mg/Codeine 240 mgTotal
Moderate21984910630304
Severe2593488632284
Body Weight
Body Weight(Kilograms)PlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 2400 mgAcetaminophen 2400 mg/Codeine 240 mgTotal
Mean71.21 ± 16.3372.53 ± 16.6871.02 ± 15.9672.24 ± 16.8169.43 ± 13.9971.76 ± 16.29
Duration of Surgery
Duration of Surgery(Hours)PlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 2400 mgAcetaminophen 2400 mg/Codeine 240 mgTotal
Mean0.14 ± 0.060.13 ± 0.060.15 ± 0.080.14 ± 0.060.13 ± 0.060.14 ± 0.06
Height
Height(Centimeters)PlaceboEtoricoxib 90 mgEtoricoxib 120 mgIbuprofen 2400 mgAcetaminophen 2400 mg/Codeine 240 mgTotal
Mean171.03 ± 8.91168.39 ± 9.95167.92 ± 10.07168.50 ± 9.05168.38 ± 9.86168.56 ± 9.59

3 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Brown JD, Daniels SE, Bandy DP, Ko AT, Gammaitoni A, Mehta A, Boice JA, Losada MC, Peloso PM. Evaluation of multiday analgesia with etoricoxib in a double-blind, randomized controlled trial using the postoperative third-molar extraction dental pain model. Clin J Pain. 2013 Jun;29(6):492-8. doi: 10.1097/AJP.0b013e318260c144. PubMed 23247002 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Dec 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2008
First posted
Jun 10, 2008
Start
Jun 2008
Primary completionActual
Dec 2008
CompletionActual
Jan 2009
Results first posted
Jan 29, 2010
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00694369
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jun 10, 2008
Start date
Jun 2008
Primary completion
Dec 2008
Completion
Jan 2009
Results posted
Jan 29, 2010
Last update
Feb 9, 2022

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etoricoxib

Start the discussion